Literature DB >> 22256987

Interactions of the antimalarial drug methylene blue with methemoglobin and heme targets in Plasmodium falciparum: a physico-biochemical study.

Olga Blank1, Elisabeth Davioud-Charvet, Mourad Elhabiri.   

Abstract

AIMS: Resistance of Plasmodium falciparum to drugs has led to renewed interest of redox-active methylene blue (MB) for which no resistance has been reported so far. Moreover, MB displays unique interactions with glutathione reductase (GR). However, the mechanisms of action/interaction with potential targets of MB are yet to be elucidated. Our physico-biochemical study on MB and relevant hematin-containing targets was performed under quasi-physiological conditions.
RESULTS: The water deprotonation of the Fe(III)protoporphyrin dimer, the major building block of β-hematin, was studied. At pH 6, the predominant dimer possesses water coordinated to both metals. Below pH 6, spontaneous precipitation of β-hematin occurred reminiscent of hemozoin biomineralization at pH 5.0-5.5 in the food vacuole of the malarial parasite. MB also forms dimers (K(Dim)=6800 M(-1)) and firmly binds to hematin in a 2:1 hematin:MB sandwich complex (K(D)=3.16 μM). MB bioactivation catalyzed by GR induces efficient methemoglobin(Fe(III)) [metHb(Fe(III))] reduction to hemoglobin(Fe(II)). The reduction rate, mediated by leucomethylene blue (LMB), was determined (k(metHb)(red)=991 M(-1)·s(-1)) in an assay coupled to the GR/reduced form of nicotinamide adenine dinucleotide phosphate system. INNOVATION AND
CONCLUSION: Our work provides new insights into the understanding of (i) how MB interacts with hematin-containing targets, (ii) other relevant MB properties in corroboration with the distribution of the three major LMB species as a function of pH, and (iii) how this redox-active cycler induces efficient catalytic reduction of metHb(Fe(III)) to hemoglobin(Fe(II)) mediated by oxidoreductases. These physico-biochemical parameters of MB open promising perspectives for the interpretation of the pharmacology and pathophysiology of malaria and possibly new routes for antimalarial drug development.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22256987     DOI: 10.1089/ars.2011.4239

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  12 in total

1.  Synthesis and biological evaluation of 1,4-naphthoquinones and quinoline-5,8-diones as antimalarial and schistosomicidal agents.

Authors:  Don Antoine Lanfranchi; Elena Cesar-Rodo; Benoît Bertrand; Hsin-Hung Huang; Latasha Day; Laure Johann; Mourad Elhabiri; Katja Becker; David L Williams; Elisabeth Davioud-Charvet
Journal:  Org Biomol Chem       Date:  2012-07-10       Impact factor: 3.876

2.  The antimalarial activities of methylene blue and the 1,4-naphthoquinone 3-[4-(trifluoromethyl)benzyl]-menadione are not due to inhibition of the mitochondrial electron transport chain.

Authors:  Katharina Ehrhardt; Elisabeth Davioud-Charvet; Hangjun Ke; Akhil B Vaidya; Michael Lanzer; Marcel Deponte
Journal:  Antimicrob Agents Chemother       Date:  2013-02-25       Impact factor: 5.191

3.  QSAR modeling and chemical space analysis of antimalarial compounds.

Authors:  Pavel Sidorov; Birgit Viira; Elisabeth Davioud-Charvet; Uko Maran; Gilles Marcou; Dragos Horvath; Alexandre Varnek
Journal:  J Comput Aided Mol Des       Date:  2017-04-03       Impact factor: 3.686

Review 4.  A physico-biochemical study on potential redox-cyclers as antimalarial and anti-schistosomal drugs.

Authors:  Laure Johann; Don Antoine Lanfranchi; Elisabeth Davioud-Charvet; Mourad Elhabiri
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 5.  Plasmodium drug targets outside the genetic control of the parasite.

Authors:  David J Sullivan
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 6.  1,4-naphthoquinones and other NADPH-dependent glutathione reductase-catalyzed redox cyclers as antimalarial agents.

Authors:  Didier Belorgey; Don Antoine Lanfranchi; Elisabeth Davioud-Charvet
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

7.  Nucleoside-lipid-based nanocarriers for methylene blue delivery: potential application as anti-malarial drug.

Authors:  Koffi Kowouvi; Bruno Alies; Mathieu Gendrot; Alexandra Gaubert; Gaelle Vacher; Karen Gaudin; Joel Mosnier; Bruno Pradines; Philippe Barthelemy; Luc Grislain; Pascal Millet
Journal:  RSC Adv       Date:  2019-06-17       Impact factor: 4.036

8.  Antimalarial NADPH-Consuming Redox-Cyclers As Superior Glucose-6-Phosphate Dehydrogenase Deficiency Copycats.

Authors:  Max Bielitza; Didier Belorgey; Katharina Ehrhardt; Laure Johann; Don Antoine Lanfranchi; Valentina Gallo; Evelin Schwarzer; Franziska Mohring; Esther Jortzik; David L Williams; Katja Becker; Paolo Arese; Mourad Elhabiri; Elisabeth Davioud-Charvet
Journal:  Antioxid Redox Signal       Date:  2015-04-14       Impact factor: 8.401

9.  Pharmacomodulation of the Antimalarial Plasmodione: Synthesis of Biaryl- and N-Arylalkylamine Analogues, Antimalarial Activities and Physicochemical Properties.

Authors:  Karène Urgin; Mouhamad Jida; Katharina Ehrhardt; Tobias Müller; Michael Lanzer; Louis Maes; Mourad Elhabiri; Elisabeth Davioud-Charvet
Journal:  Molecules       Date:  2017-01-19       Impact factor: 4.411

10.  The Redox Cycler Plasmodione Is a Fast-Acting Antimalarial Lead Compound with Pronounced Activity against Sexual and Early Asexual Blood-Stage Parasites.

Authors:  Katharina Ehrhardt; Christiane Deregnaucourt; Alice-Anne Goetz; Tzvetomira Tzanova; Valentina Gallo; Paolo Arese; Bruno Pradines; Sophie H Adjalley; Denyse Bagrel; Stephanie Blandin; Michael Lanzer; Elisabeth Davioud-Charvet
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.